Skip to main content
Erschienen in: Supportive Care in Cancer 9/2017

20.04.2017 | Original Article

Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis

verfasst von: A. R. T. Bergin, E. Hovey, A. Lloyd, G. Marx, P. Parente, T. Rapke, P. de Souza

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Fatigue is a prevalent and debilitating side effect of docetaxel chemotherapy in metastatic prostate cancer. A better understanding of the kinetics and nature of docetaxel-related fatigue may provide a framework for intervention.

Methods

This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]. The pattern of fatigue was analysed using the MDASI (MD Anderson Symptom Inventory) score. The impact of modafinil, cumulative docetaxel exposure, age and smoking status on fatigue kinetics were explored. Fatigue-related symptoms were assessed using the SOMA6 (fatigue and related symptoms) subset of the SPHERE (Somatic and Psychological Health Report). Mood was tracked using the short form 36 health survey questionnaire (SF-36).

Results

Across four docetaxel cycles, fatigue scores were higher in the first week and decreased over weeks two and three. Whilst men randomised to modafinil had reduced fatigue scores, cumulative docetaxel had little impact. Younger men (55–68 years) had significantly reduced fatigue scores, whereas current and ex-smokers had higher scores. There was no significant change in mood status or haemoglobin across treatment cycles. Men described both ‘somnolence’ and ‘muscle fatigue’ contributing significantly to their symptom complex.

Conclusions

Assessment and management of docetaxel-related fatigue remains an important challenge. Given the complex, multifactorial nature of fatigue, identification through structured interview and interventions targeted to specific ‘at risk’ groups may be the most beneficial. Understanding the temporal pattern (kinetics) and nature of fatigue is critical to guide this process.
Literatur
1.
Zurück zum Zitat Hovey E, Souza P de, Marx G, et al (2014) Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer 22:1233–1242. doi: 10.1007/s00520-013-2076-0 Hovey E, Souza P de, Marx G, et al (2014) Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer 22:1233–1242. doi: 10.​1007/​s00520-013-2076-0
2.
Zurück zum Zitat Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13–19PubMed Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13–19PubMed
3.
Zurück zum Zitat Hofman M, Morrow GR, Roscoe JA et al (2004) Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices. Cancer 101:851–857. doi:10.1002/cncr.20423 CrossRefPubMed Hofman M, Morrow GR, Roscoe JA et al (2004) Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices. Cancer 101:851–857. doi:10.​1002/​cncr.​20423 CrossRefPubMed
4.
Zurück zum Zitat Berger AM, Mooney K, Alvarez-Perez A et al (2015) Cancer-related fatigue, version 2.2015. J Natl Compr Cancer Netw 13:1012–1039CrossRef Berger AM, Mooney K, Alvarez-Perez A et al (2015) Cancer-related fatigue, version 2.2015. J Natl Compr Cancer Netw 13:1012–1039CrossRef
6.
Zurück zum Zitat Jacobsen PB, Hann DM, Azzarello LM et al (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manag 18:233–242CrossRef Jacobsen PB, Hann DM, Azzarello LM et al (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manag 18:233–242CrossRef
7.
Zurück zum Zitat Evans WJ, Lambert CP (2007) Physiological basis of fatigue. Am J Phys Med Rehabil 86:S29–S46CrossRefPubMed Evans WJ, Lambert CP (2007) Physiological basis of fatigue. Am J Phys Med Rehabil 86:S29–S46CrossRefPubMed
8.
Zurück zum Zitat (2002) Chronic fatigue syndrome. Clinical practice guidelines--2002. Med J Aust 176 Suppl:S23–56 (2002) Chronic fatigue syndrome. Clinical practice guidelines--2002. Med J Aust 176 Suppl:S23–56
10.
Zurück zum Zitat Hadzi-Pavlovic D, Hickie IB, Wilson AJ et al (2000) Screening for prolonged fatigue syndromes: validation of the SOFA scale. Soc Psychiatry Psychiatr Epidemiol 35:471–479CrossRefPubMed Hadzi-Pavlovic D, Hickie IB, Wilson AJ et al (2000) Screening for prolonged fatigue syndromes: validation of the SOFA scale. Soc Psychiatry Psychiatr Epidemiol 35:471–479CrossRefPubMed
11.
Zurück zum Zitat Bennett BK, Goldstein D, Chen M et al (2014) Characterization of fatigue states in medicine and psychiatry by structured interview. Psychosom Med 76:379–388CrossRefPubMed Bennett BK, Goldstein D, Chen M et al (2014) Characterization of fatigue states in medicine and psychiatry by structured interview. Psychosom Med 76:379–388CrossRefPubMed
13.
Zurück zum Zitat Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. doi:10.1056/NEJMoa041318 CrossRefPubMed Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. doi:10.​1056/​NEJMoa041318 CrossRefPubMed
14.
Zurück zum Zitat Tannock IF, Wit R de, Berry WR, et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi: 10.1056/NEJMoa040720 Tannock IF, Wit R de, Berry WR, et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi: 10.​1056/​NEJMoa040720
15.
Zurück zum Zitat James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177. doi:10.1016/S0140-6736(15)01037-5 CrossRefPubMedPubMedCentral James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177. doi:10.​1016/​S0140-6736(15)01037-5 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Al-Batran S-EE, Hozaeel W, Tauchert FK et al (2015) The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 26:1244–1248. doi:10.1093/annonc/mdv129 CrossRefPubMed Al-Batran S-EE, Hozaeel W, Tauchert FK et al (2015) The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 26:1244–1248. doi:10.​1093/​annonc/​mdv129 CrossRefPubMed
19.
Zurück zum Zitat Awada A, Hendlisz A, Christensen O et al (2012) Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 48:465–474. doi:10.1016/j.ejca.2011.12.026 CrossRefPubMed Awada A, Hendlisz A, Christensen O et al (2012) Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 48:465–474. doi:10.​1016/​j.​ejca.​2011.​12.​026 CrossRefPubMed
21.
Zurück zum Zitat Hickie IB, Davenport TA, Hadzi-Pavlovic D et al (2001) Development of a simple screening tool for common mental disorders in general practice. Med J Aust 175(Suppl):S10–S17PubMed Hickie IB, Davenport TA, Hadzi-Pavlovic D et al (2001) Development of a simple screening tool for common mental disorders in general practice. Med J Aust 175(Suppl):S10–S17PubMed
23.
Zurück zum Zitat Farivar S, Cunningham W, Hays R (2007) Correlated physical and mental health summary scores for the SF-36 and SF-12 health survey, V.1. Health Qual Life Out 5:1–8. doi:10.1186/1477-7525-5-54 CrossRef Farivar S, Cunningham W, Hays R (2007) Correlated physical and mental health summary scores for the SF-36 and SF-12 health survey, V.1. Health Qual Life Out 5:1–8. doi:10.​1186/​1477-7525-5-54 CrossRef
25.
Zurück zum Zitat Glaus A, Crow R, Hammond S (1996) A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4:82–96CrossRefPubMed Glaus A, Crow R, Hammond S (1996) A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4:82–96CrossRefPubMed
27.
Zurück zum Zitat Cella D, Davis K, Breitbart W, Curt G (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391CrossRefPubMed Cella D, Davis K, Breitbart W, Curt G (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391CrossRefPubMed
31.
Zurück zum Zitat Jones D, Zhao F, Fisch MJ et al (2014) The validity and utility of the MD Anderson symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 12:41–49. doi:10.1016/j.clgc.2013.07.003 CrossRefPubMed Jones D, Zhao F, Fisch MJ et al (2014) The validity and utility of the MD Anderson symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 12:41–49. doi:10.​1016/​j.​clgc.​2013.​07.​003 CrossRefPubMed
33.
Zurück zum Zitat Yennurajalingam S, Frisbee-Hume S, Palmer JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082. doi:10.1200/JCO.2012.44.4661 CrossRefPubMed Yennurajalingam S, Frisbee-Hume S, Palmer JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082. doi:10.​1200/​JCO.​2012.​44.​4661 CrossRefPubMed
37.
38.
Zurück zum Zitat Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults Cochrane Database Syst Rev:CD006953. doi:10.1002/14651858.CD006953.pub2 Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults Cochrane Database Syst Rev:CD006953. doi:10.​1002/​14651858.​CD006953.​pub2
41.
Zurück zum Zitat Bower JE, Ganz PA, Desmond KA et al (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743–753CrossRefPubMed Bower JE, Ganz PA, Desmond KA et al (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743–753CrossRefPubMed
Metadaten
Titel
Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis
verfasst von
A. R. T. Bergin
E. Hovey
A. Lloyd
G. Marx
P. Parente
T. Rapke
P. de Souza
Publikationsdatum
20.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3706-8

Weitere Artikel der Ausgabe 9/2017

Supportive Care in Cancer 9/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.